福瑞医科
(300049)
| 流通市值：117.66亿 | | | 总市值：133.44亿 |
| 流通股本：2.34亿 | | | 总股本：2.65亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 360,140,767.62 | 1,595,388,937.81 | 1,101,043,939.95 | 713,416,420.63 |
| 营业收入 | 360,140,767.62 | 1,595,388,937.81 | 1,101,043,939.95 | 713,416,420.63 |
| 二、营业总成本 | 276,499,345 | 1,213,306,309.13 | 860,482,026.38 | 587,337,842.57 |
| 营业成本 | 90,421,329.81 | 399,359,578.05 | 272,390,465.65 | 176,481,210.32 |
| 税金及附加 | 2,866,288.41 | 10,992,163.08 | 6,727,452.68 | 6,712,257.8 |
| 销售费用 | 90,454,277.02 | 390,245,601.39 | 281,163,977.42 | 186,709,894.72 |
| 管理费用 | 72,251,303.87 | 284,948,972.96 | 200,209,632.1 | 147,324,057.04 |
| 研发费用 | 31,522,653.2 | 111,203,556.9 | 81,187,578.74 | 49,959,538.74 |
| 财务费用 | -11,016,507.31 | 16,556,436.75 | 18,802,919.79 | 20,150,883.95 |
| 其中:利息费用 | 910,858.33 | 3,224,057.79 | 2,251,248.53 | 1,462,243.45 |
| 其中:利息收入 | 4,617,831.15 | 19,289,158.65 | 14,357,077.28 | 9,973,974.24 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | 25,291,768.37 | 1,215,100.2 | - |
| 加:投资收益 | -2,029,487.59 | -8,457,731.9 | -4,980,955.18 | -3,631,675.79 |
| 资产处置收益 | -89,371.61 | 378,455.47 | 415,560.54 | -346,489.03 |
| 资产减值损失(新) | - | -33,517,494.97 | -329,874.45 | 65,902.89 |
| 信用减值损失(新) | -3,756,834.27 | 1,755,702.22 | -7,518,003.44 | -4,063,507.36 |
| 其他收益 | 1,218,823.12 | 763,236.4 | 279,006.5 | 192,890.44 |
| 四、营业利润 | 78,984,552.27 | 368,296,564.27 | 229,642,747.74 | 118,295,699.21 |
| 加:营业外收入 | 480.62 | 843,121.66 | 30,435.72 | 16,607.69 |
| 减:营业外支出 | 5,904,360.79 | 18,578,209.69 | 5,857,510.51 | 3,904,299.39 |
| 五、利润总额 | 73,080,672.1 | 350,561,476.24 | 223,815,672.95 | 114,408,007.51 |
| 减:所得税费用 | 20,958,336.98 | 92,140,691.23 | 61,819,006.45 | 36,451,431.55 |
| 六、净利润 | 52,122,335.12 | 258,420,785.01 | 161,996,666.5 | 77,956,575.96 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 52,122,335.12 | 258,420,785.01 | 161,996,666.5 | 77,956,575.96 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 31,794,294.84 | 154,089,068.25 | 111,886,162.73 | 51,933,983.78 |
| 少数股东损益 | 20,328,040.28 | 104,331,716.76 | 50,110,503.77 | 26,022,592.18 |
| 扣除非经常损益后的净利润 | 33,401,661.37 | 134,599,041.9 | 111,449,781.11 | 53,323,012.87 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.12 | 0.58 | 0.43 | 0.2 |
| (二)稀释每股收益 | 0.12 | 0.58 | 0.43 | 0.2 |
| 八、其他综合收益 | -47,067,187.84 | 98,609,354.51 | 73,720,280.81 | 46,038,444.3 |
| 归属于母公司股东的其他综合收益 | -30,460,123.62 | 74,413,565.3 | 46,416,507.09 | 14,842,439.13 |
| 九、综合收益总额 | 5,055,147.28 | 357,030,139.52 | 235,716,947.31 | 123,995,020.26 |
| 归属于母公司股东的综合收益总额 | 1,334,171.22 | 228,502,633.55 | 158,302,669.82 | 66,776,422.91 |
| 归属于少数股东的综合收益总额 | 3,720,976.06 | 128,527,505.97 | 77,414,277.49 | 57,218,597.35 |
| 公告日期 | 2026-04-28 | 2026-03-25 | 2025-10-29 | 2025-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |